Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 26NSCLC 4Brain Neoplasms 4Adenocarcinoma of Lung 4Meningeal Carcinomatosis 3Lung Neoplasms 3Pleural Effusion, Malignant 1Multiple Primary Lung Cancers 1Advanced NSCLC Patients With T790M 1

Interventions

Paclitaxel 5Carboplatin 5Docetaxel 4Cisplatin 4Bevacizumab 4Taxes 3Drug Therapy 3Gemcitabine 2Fluorodeoxyglucose F18 2Cetuximab 2saracatinib 1endostar protein 1cediranib 1aflutinib 1Zoledronic Acid 1X-Rays 1Vinorelbine 1Thoracic Surgery, Video-Assisted 1Spectrum Analysis 1Silver Nitrate 1Saline Solution 1Radiotherapy, Conformal 1Radiation 1Pleurodesis 1Pemetrexed 1Nivolumab 1Naproxen 1N-(5-(2,3-dihydrobenzofuryl)sulfonyl)-N'-(3,4-dichlorophenyl)urea 1Morphine 1Metformin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Pleural Effusion, Malignant × aflutinib × Clear all
NCT07482605 2026-03-20

Furmonertinib Plus Radiotherapy for EGFR+ NSCLC With Pleural Effusion

Jiangmen Central Hospital

Phase 2 Not yet recruiting
63 enrolled
Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pleural Effusion, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡